Review of 11 national policies for rare diseases in the context of key patient needs
Author:
Funder
Pfizer
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Genetics (clinical),General Medicine
Link
http://link.springer.com/content/pdf/10.1186/s13023-017-0618-0.pdf
Reference69 articles.
1. Franco P. Orphan drugs: the regulatory environment. Drug Discov Today. 2013;18(3–4):163–72.
2. Haffner ME, Whitley J, Moses M. Two decades of orphan product development. Nat Rev Drug Discov. 2002;1(10):821–5.
3. Orphan Drug Act, Public Law 97-414. 97th Congress. January 4, 1983 (US).2049-2066.
4. Orphan Drug amendments of 1985, Public Law 99, 91, 15 August 1985 (US).
5. Orphan Drug amendments of 1988, Public Law 100-290, 18 April 1988 (US).
Cited by 135 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. A comprehensive review on the current status of CRISPR based clinical trials for rare diseases;International Journal of Biological Macromolecules;2024-10
2. Artificial intelligence empowering rare diseases: a bibliometric perspective over the last two decades;Orphanet Journal of Rare Diseases;2024-09-13
3. Operational description of rare diseases: a reference to improve the recognition and visibility of rare diseases;Orphanet Journal of Rare Diseases;2024-09-11
4. Health-Related Quality of Life and Mental Health of Parents of Children with Pediatric Abdominal Tumors;Children;2024-08-16
5. Rare disease publishing trends worldwide and in China: a citespace-based bibliometric study;2024-06-28
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3